US post-recall inspection fees "could compromise integrity", says House Panel member
This article was originally published in Clinica
Executive Summary
The US FDA's proposed new user fee for re-inspections could come up against opposition in the Congress. The ranking Democrat on the House panel that oversees the FDA's budget raised concerns last week that the programme could compromise the integrity of inspections.